Doxycycline foam - Foamix

Drug Profile

Doxycycline foam - Foamix

Alternative Names: FDX-104; FDX104 antibiotic foam

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Foamix
  • Class Antibacterials; Antimalarials; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Exanthema

Most Recent Events

  • 03 Apr 2017 Phase-II development for Exanthema (Chemotherapy-induced, Prevention) is ongoing in Israel (Topical, Foam) (Foamix website, April 2017)
  • 31 May 2016 Updated efficacy and adverse events data from a phase II trial in Exanthema released by Foamix
  • 10 May 2016 Foamix plans toxicology studies and a MUSE/Bridge study
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top